ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / QNTM / earnings
TXMD (34) AYTU (27) COCP (36) AKTX (37) ⌘ Pro Terminal →

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) Next Earnings Date & Expected ±12.5% Move

$2.26 -5.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.24

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $20.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QNTM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QNTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ: QNTM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.26 (-5.04% 1D, market cap $20.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, QNTM ranks #342 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QNTM compare to TXMD and AYTU in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNTM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TXMD (TherapeuticsMD Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -12.9%, cap $20.8M) and AYTU (Aytu BioPharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M). Among the 5-stock peer group, QNTM leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QNTM?
▼

For Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #342 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.24 (-1.10%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.3% Base Target
$13 Bull$2 Base$2 Bear
📬 FREE QNTM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QNTM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY QNTM SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($564.3K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$2.89-15.9% Next Q
Q2 (-2Q)
51
Grade C-$2.43-4.5% Next Q
Q3 (-1Q)
49
Grade D$2.32-2.6% Next Q
Current
46
Grade D$2.26-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QNTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QNTM currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.08) and Max Pain ($2.37) forces dealer call-delta covering toward $13.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QNTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QNTM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.28 Expected Swing
$1.98 (-12.5%)Spot $2.26$2.54 (+12.5%)
MODEL EARNINGS SETUP GAUGE

QNTM Quantitative Pre-Earnings Setup: 46/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (46/100)Model Risk Weight (54/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QNTM)

  • ✓Walkthrough of QNTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QNTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.54%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.44H $2.44L $2.26C $2.26VOL 76.9K
RES: $4.31SUP: $1.95SMA50: $3.08SMA200: $3.83
$11.42$8.89$6.36$3.83$1.31RES $4.31SUP $1.95$2.262026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QNTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QNTM Butterfly Map → + Track QNTM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QNTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QNTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QNTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QNTM)

Health Care Rank #342 of 1015 ⚔️ TXMD vs QNTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QNTM vs. TXMD, AYTU, COCP, AKTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) ranks #342 by composite RQD confidence (46/100, grade D) and #830 by equity capitalization ($20.2M). Within this direct 5-issuer industry benchmark cohort, QNTM leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QNTM ACTIVE
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
D 46/100 — — — -5.04% $20.2M Benchmark Subject
TXMD
TherapeuticsMD Inc.
E 34/100 — — -12.9% +0.56% $20.8M /txmd-vs-qntm →
AYTU
Aytu BioPharma Inc.
E 27/100 — 69.0% -35.0% +0.52% $21.0M /aytu-vs-qntm →
COCP
Cocrystal Pharma Inc.
D- 36/100 — — -35.0% +6.53% $19.2M /cocp-vs-qntm →
AKTX
Akari Therapeutics plc ADS
D- 37/100 — — -35.0% -4.85% $18.8M /aktx-vs-qntm →

2. QNTM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $20.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. QNTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QNTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ: QNTM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.26 (-5.04% 1D, market cap $20.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, QNTM ranks #342 in composite RQD confidence.

How does QNTM compare to TXMD and AYTU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNTM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TXMD (TherapeuticsMD Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -12.9%, cap $20.8M) and AYTU (Aytu BioPharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M). Among the 5-stock peer group, QNTM leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QNTM?

For Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #342 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QNTM trading relative to its 50-day, 200-day, and 52-week technical levels?

QNTM last traded at $2.26 (-5.04% on volume of 57,400 shares), positioning the stock -26.62% below its 50-day simple moving average ($3.08) and -40.99% below its 200-day simple moving average ($3.83). Across its 52-week range of $2.07 to $12.42, QNTM sits at the 1.8% percentile with a 14-day RSI of 36.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.98 to $2.54).

Direct Sub-Reports: QNTM RQD Cockpit QNTM 12M Forecast QNTM Earnings & Move QNTM Dividends & DRIP QNTM Insiders & 13F QNTM Whale Options QNTM Profit Sankey QNTM News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

QNTM — Quantum Biopharma Ltd. Class B Subordinate Voting Shares: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.26 (-5.04% 1D, market capitalization $20.2M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.07 – $12.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlations and upstream or downstream dependencies cannot be assessed from the source data.

  • Key Question #1: Can QNTM sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $12.42 52-week high?
  • Key Question #3: How sensitive is QNTM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

QNTM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QNTM Debate Forum (3) ↓
🔴 RISK WATCH Yahoo Finance • 26d ago
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QNTM Bull vs. Bear Conversation Board — What's Your Call at $2.26?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QNTM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QNTM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $2.81 (+18.1%)
📌 Pinned Debate

Forensic balance-sheet pillar is the strongest component at 13 / 20, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5.

Here is why I am bullish on QNTM here at $2.38: Forensic balance-sheet pillar is the strongest component at 13 / 20, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5.. Compare QNTM's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.26 are getting bought.

VolSurface_Trader 🐂 BULL

Both sides have a point here — QNTM's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $1.93 (-18.9%)
Spot @ $2.38

Whale 13F flow scores 3 / 20 and the Fundamental Cash Engine shows ROIC 0% and FCF yield 0%, pointing to weak institutional support and

I respect the product at Quantum Biopharma Ltd. Class B Subordinate Voting Shares, but the stock at $2.38 is a different story. Whale 13F flow scores 3 / 20 and the Fundamental Cash Engine shows ROIC 0% and FCF yield 0%, pointing to weak institutional support and no measurable cash return.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE